Keyword: Spark Therapeutics

After winning European approval for its gene therapy Luxturna, Novartis is working on individual reimbursement plans with member countries.

Emgality will likely chase Amgen and Novartis’ first-in-class Aimovig and Teva's Ajovy in the CGRP migraine field.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

Never underestimate the power of positivity, which triumphed in the latest round of voting in FiercePharma’s drug-naming shootout.

Intent to focus on the first -ever gene therapy launch in the U.S., Spark Therapeutics has licensed voretigene neparvovec to Novartis in all other markets.

The J.P. Morgan Healthcare Conference was a great place to suss out the general biopharma mood as 2018 begins.

Payers are now holding up Spark's $850,000 gene therapy as an example of how innovative drug developers can help payers afford pricey new treatments.

Roche picked up FDA approval in November for its hemophilia A drug Hemlibra (emicizumab)—and now it has taken a big step forward in Europe.

The numbers behind NICE's choice to endorse Strimvelis show just how tough it can be to make money from gene therapy.

There's a new medicine atop of pharma's global pricing charts, and it's Spark Therapeutics' Luxturna.